Novartis reported the FDA has agreed to give priority review of its drug Femara, intended for treatment of post-menopausal women with breast cancer who have had five years of standard therapy. Already approved to treat breast cancer that has spread to other parts of the body, Femara is now being considered as a possible treatment for earlier stages of the disease. A decision on approval of the drug is expected later this year.

Full Story:

Related Summaries